Spruce Biosciences Inc is a biopharmaceutical company focused on the development of innovative therapies for patients with rare endocrine disorders
The company is committed to addressing unmet medical needs through the advancement of its proprietary drug candidates, particularly targeting conditions related to adrenal insufficiency. By harnessing cutting-edge scientific research and clinical expertise, Spruce aims to bring effective treatment options to patients, ultimately enhancing their quality of life and managing complex hormonal imbalances associated with these disorders.
Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive disorder, using the Cortibon Genetic Selection Tool.
PFE came out with quarterly earnings of $0.82 per share, beating the our eimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago.
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.35% to 38,905.20 while the NASDAQ fell 0.13% to 16,156.28. The S&P 500 also fell, dropping, 0.25% to 5,152.46.
Shares of Limbach Holdings, Inc. (NASDAQLMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.30% to 38,926.22 while the NASDAQ fell 0.44% to 16,107.04. The S&P 500 also fell, dropping, 0.39% to 5,145.38.
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.11% to 39,084.58 while the NASDAQ rose 0.30% to 16,226.13. The S&P 500 also rose, gaining, 0.14% to 5,172.33.
Gainers Biocept, Inc. (NASDAQBIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics.
